Why the study?
Fluoropyrimidine-associated cardiotoxicity can be a therapy-limiting adverse effect that largely depends on the mode of fluoropyrimidine administration.
What are the strategies for re-challenge after incident 5-fluorouracil-induced cardiotoxicity in patients with colorectal carcinoma?
What are the strategies for re-challenge after incident 5-fluorouracil-induced cardiotoxicity in patients with colorectal carcinoma?
Highlights strategies for managing and re-challenging patients with 5-fluorouracil-induced cardiotoxicity to minimize recurrence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Anju Nohria (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: